Women with advanced breast cancer who progress on prior CDK4/6 inhibition can still benefit from second-line treatment with a CDK4/6 inhibitor as part of combination therapy.

Researchers from USask have identified a potential target for eliminating breast cancer cells. The team was led by Dr. Franco ...

Efti plus Keytruda and chemo achieved a 61% response rate in first-line advanced non-squamous non–small cell lung cancer, ...

Enliven Therapeutics has decided against taking its phase 1-stage solid tumor drug into further development next year in ...

Sr. Ann courageously shares her journey — from the moment of diagnosis to the treatments, emotional battles, and the unwavering faith and support that have fueled her recovery.